Cash/Burn From SEC Filing For Period: 

Q1 '20

ICPT

Intercept Pharmaceuticals

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

Cash

$549M

Burn Rate

-$93M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

OCALIVA® (obeticholic acid)

Primary Biliary Cholangitis (PBC)

Quarterly Sales (Approved)

August 10, 2020

Ocaliva

Adult nonalcoholic steatohepatitis (NASH)

Report out on post-CRL FDA meeting

August 10, 2020

Ocaliva

Primary Sclerosing Cholangitis

TBD

Ocaliva

Biliary Atresia

Phase 2

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

Trilaciclib NDA Filing (GTHX)...

We are fans of GTHX and hope things go well. But we are worried if NDA for Trilaciclib in NSCLC is accepted and accelerated date is set, that expedited PDUFA is too rushed for FDA during a pandemic. S...

ICPT CRL for Ocaliva
...

Intercept Pharmaceuticals, Inc. received a Complete Response Letter from the U.S. FDA for the NDA for Ocaliva which is used for Adult nonalcoholic steatohepatitis (NASH). The FDA stated that the CRL w...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon